The newest update to the COVID-19 vaccine reached pharmacies as infections in Indiana began to rise. Members of our audience ...

BioNTech has been boosted a wave of enthusiasm over another company’s cancer drug, which has turned the biopharma industry ...

BioNTech stock has climbed 25% over four days as the German biotech rides a round of cancer treatment success from Summit ...

The BioNTech SE ADR BNTX inched 0.69% higher to $113.05 Monday, on what proved to be an all-around positive trading session ...

In July, a High Court judge delivered a mixed ruling in the long-running dispute that has pitted pharmaceutical giant Pfizer ...

BioNTech BNTX has been analyzed by 8 analysts in the last three months, revealing a diverse range of perspectives from ...

The decision not to advance the vaccine into Phase III trials effectively ends GSK's ambition to bring the first HSV vaccine ...

Today, Benzinga 's options scanner spotted 26 uncommon options trades for BioNTech. This isn't normal. The overall sentiment ...

H.C. Wainwright analyst Robert Burns has reiterated their bullish stance on BNTX stock, giving a Buy rating on September 9. Robert Burns has ...

In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on BioNTech SE (BNTX – Research Report), with ...

The newest update to the COVID-19 vaccine reached pharmacies as infections in Indiana began to rise. Members of our audience ...

BioNTech SE ADR closed $10.99 short of its 52-week high ($115.99), which the company reached on September 14th.